Determinants of COVID-19 vaccine acceptance in a high infection-rate country: a cross-sectional study in Russia

Main Article Content

Keywords

COVID-19 Vaccines, Immunization Programs, Vaccination, Vaccination Refusal, Attitude, Health Knowledge, Attitudes, Practice, COVID-19, SARS-CoV-2, Pandemics, Multivariate Analysis, Surveys and Questionnaires, Russia

Abstract

Background: COVID-19 vaccine development is proceeding at an unprecedented pace. Once COVID-19 vaccines become widely available, it will be necessary to maximize public vaccine acceptance and coverage.


Objective: This research aimed to analyze the predictors of COVID-19 vaccine acceptance in Russia.


Methods: A cross-sectional online survey was conducted among Russian adults from September 26th to November 9th, 2020. Predictors of the intent to take up COVID-19 vaccination were explored using logistic regression.


Results: Out of 876 participants, 365 (41.7%) would be willing to receive the vaccine if it became available. Acceptance increased for a vaccine with verified safety and effectiveness (63.2%). Intention to receive the COVID-19 vaccine was relatively higher among males (aOR=2.37, 95% CI 1.41-4.00), people with lower monthly income (aOR=2.94, 95%CI 1.32-6.57), and with positive trust in the healthcare system (aOR=2.73, 95% CI 1.76-4.24). The Russian people were more likely to accept the COVID-19 vaccine if they believed that the vaccine reduces the risk of virus infection (aOR=8.80, 95%CI 5.21-14.87) or relieves the complications of the disease (aOR=10.46, 95%CI 6.09-17.96). Other barriers such as being unconcerned about side-effects (aOR=1.65, 95%CI 1.03-2.65) and the effectiveness and safety of the vaccination (aOR=2.55, 95%CI 1.60-4.08), also affected acceptance.


Conclusions: The study showed the usefulness of the health belief model constructs in understanding the COVID-19 vaccination acceptance rate in the Russian population. This rate was influenced by sociodemographic and health-related characteristics, and health beliefs. These findings might help guide future efforts for policymakers and stakeholders to improve vaccination rates by enhancing trust in the healthcare system.

Abstract 2761 | pdf Downloads 1303 online appendix Downloads 98

References

1. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669-677. https://doi.org/10.1016/s1473-3099(20)30243-7
2. Weekly operational update on COVID-19 - 30 November 2020. https://www.who.int/publications/m/item/weekly-operational-update---30-november-2020 (accessed Mar 10, 2021).
3. Chhetri JK, Chan P, Arai H, et al. Prevention of COVID-19 in Older Adults: A Brief Guidance from the International Association for Gerontology and Geriatrics (IAGG) Asia/Oceania region. J Nutr Health Aging. 2020;24(5):471-472. https://doi.org/10.1007/s12603-020-1359-7
4. Lim WS, Liang CK, Assantachai P, et al. COVID-19 and older people in Asia: Asian Working Group for Sarcopenia calls to actions. Geriatr Gerontol Int. 2020;20(6):547-558. https://doi.org/10.1111/ggi.13939
5. Harapan H, Wagner AL, Yufika A, et al. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. Front Public Health. 2020;8:381. https://doi.org/10.3389/fpubh.2020.00381
6. Barberia LG, Gómez EJ. Political and institutional perils of Brazil's COVID-19 crisis. Lancet. 2020;396(10248):367-368. https://doi.org/10.1016/s0140-6736(20)31681-0
7. Alfano V, Ercolano S. The Efficacy of Lockdown Against COVID-19: A Cross-Country Panel Analysis. Appl Health Econ Health Policy. 2020;18(4):509-517. https://doi.org/10.1007/s40258-020-00596-3
8. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288:198114. https://doi.org/10.1016/j.virusres.2020.198114
9. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed Mar 10, 2021).
10. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020;382(21):1969-1973. https://doi.org/10.1056/nejmp2005630
11. The New York Times. Covid-19 Vaccine Tracker: Latest Updates. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html (accessed Mar 10, 2021).
12. Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11:585354. https://doi.org/10.3389/fimmu.2020.585354
13. Liebowitz D, Gottlieb K, Kolhatkar NS, et al. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. Lancet Infect Dis. 2020;20(4):435-444. https://doi.org/10.1016/s1473-3099(19)30584-5
14. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383(25):2439-2450. https://doi.org/10.1056/nejmoa2027906
15. The New York Times. In Coronavirus Vaccine Race, China Strays From the Official Paths. https://www.nytimes.com/2020/07/16/business/china-vaccine-coronavirus.html (accessed Mar 10, 2021).
16. The New York Times. Russia Approves Coronavirus Vaccine Before Completing Tests. https://www.nytimes.com/2020/08/11/world/europe/russia-coronavirus-vaccine-approval.html (accessed Mar 10, 2021).
17. The Lancet. Salient lessons from Russia's COVID-19 outbreak. Lancet. 2020;395(10239):1739. https://doi.org/10.1016/s0140-6736(20)31280-0
18. Sun X, Wagner AL, Ji J, et al. A conjoint analysis of stated vaccine preferences in Shanghai, China. Vaccine. 2020;38(6):1520-1525. https://doi.org/10.1016/j.vaccine.2019.11.062
19. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225-228. https://doi.org/10.1038/s41591-020-1124-9
20. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495. https://doi.org/10.1016/j.eclinm.2020.100495
21. Wong LP, Alias H, Wong PF, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum Vaccin Immunother. 2020;16(9):2204-2214. https://doi.org/10.1080/21645515.2020.1790279
22. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. J Multidiscip Healthc. 2020;13:1657-1663. https://doi.org/10.2147/jmdh.s276771
23. García LY, Cerda AA. Contingent assessment of the COVID-19 vaccine. Vaccine. 2020;38(34):5424-5429. https://doi.org/10.1016/j.vaccine.2020.06.068
24. Wong LP, Alias H, Wong PF, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum Vaccin Immunother. 2020;16(9):2204-2214. https://doi.org/10.1080/21645515.2020.1790279
25. Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ; Sydney Health Literacy Lab COVID-19 group. Willingness to vaccinate against COVID-19 in Australia. Lancet Infect Dis. 2021;21(3):318-319. https://doi.org/10.1016/s1473-3099(20)30559-4
26. Statista. Would you get vaccinated against the coronavirus with Sputnik V for free in the near future? https://www.statista.com/statistics/1131987/willingness-of-russians-to-get-a-covid-19-vaccine/ (accessed Mar 10, 2021).
27. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Ann Intern Med. 2020;173(12):964-973. https://doi.org/10.7326/m20-3569
28. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020;21(7):977-982. https://doi.org/10.1007/s10198-020-01208-6
29. Habersaat KB, Jackson C. Understanding vaccine acceptance and demand-and ways to increase them. Akzeptanz und Nachfrage bezüglich Impfungen – wie lassen sie sich erhöhen?. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63(1):32-39. https://doi.org/10.1007/s00103-019-03063-0
30. Laursen J, Petersen J, Didriksen M, Iversen K, Ullum H. Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers. https://www.medrxiv.org/content/10.1101/2020.09.26.20202259v1.external-links.html (accessed Mar 10, 2021).
31. Paek HJ, Hove T. Risk perceptions and risk characteristics. https://oxfordre.com/communication/view/10.1093/acrefore/9780190228613.001.0001/acrefore-9780190228613-e-283 (accessed Mar 10, 2021).
32. Williams DJ, Noyes JM. How does our perception of risk influence decision-making? Implications for the design of risk information. Theor Issues Ergon Sci. 2007;8(1):1-35. https://doi.org/10.1080/14639220500484419
33. Perlis RH, Lazer D, Ognyanova K, Baum MA, Santillana M. The state of the nation: A 50-state COVID-19 survey: report #9: will americans vaccinate themselves and their children against COVID-19? https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/grc-740601 (accessed Mar 10, 2021).
34. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
35. Allington D, Duffy B, Wessely S, Dhavan N, Rubin J. Health-protective behaviour, social media usage and conspiracy belief during the COVID-19 public health emergency. Psychol Med. 2020;1-7. https://doi.org/10.1017/s003329172000224x
36. Catholic Health Australia. COVID-19 vaccine rationing and mass immunisation — challenges and solutions. https://www.cha.org.au/images/mission/CHA006%20Ethics%20Matters%203a.pdf (accessed Mar 10, 2021).
37. Kolff CA, Scott VP, Stockwell MS. The use of technology to promote vaccination: A social ecological model based framework. Hum Vaccin Immunother. 2018;14(7):1636-1646. https://doi.org/10.1080/21645515.2018.1477458
38. Hambidge SJ, Davidson AJ, Phibbs SL, et al. Strategies to improve immunization rates and well-child care in a disadvantaged population: a cluster randomized controlled trial. Arch Pediatr Adolesc Med. 2004;158(2):162-169. https://doi.org/10.1001/archpedi.158.2.162